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Abstract
Introduction: Ischemic heart disease (IHD) remains the leading cause of death both in Europe and in Russia. The most 
common form of IHD is stable angina. There is compelling evidence that strict adherence to clinical guidelines greatly 
contributes to mortality reduction. However, the gap between modern knowledge and use of guideline-recommended 
medications remains significant. As shown by Western practice, one of the possible solutions of this problem is regular 
conduction of pharmacoepidemiological studies.
Objective: Investigate the dynamics of drug prescription rates in patients with stable angina over the five-year period 
on the example of routine clinical practice of outpatient cardiology institution of Moscow for the purpose of further 
eliminating the prescribing gap for guideline recommended pharmacological strategies.
Materials and methods: Our research work was performed as a retrospective pharmacoepidemiological study includ-
ing two stages with five-year interval using cross-section method.
Results and discussion: We found a significant increase in use of antiplatelets (82.7 vs. 56.2%, p<0.05) and statins 
(45.6 vs. 16.1%, p<0.05). Despite the unchanged use of ACE inhibitors, the prescription rate of angiotensin receptor 
blockers II increased (14.7 vs. 9.7%, p<0.05). Analysis of anti-ischemic pharmacotherapy revealed an increase in be-
ta-adrenoblockers use (74.3 vs. 63.6%, р<0.05) and a decrease in use of long-acting nitrates (26.3 vs. 31.1%, р<0.05) 
and calcium channel blockers (35.7 vs. 39.6%, р<0.05). Significant changes were found in prescription rates and 
dosage regimens of single medications in each pharmacological group. The study results demonstrated an increase in 
frequency of capturing data on lipid profile and diet recommendations in patient records.
Conclusion: Such type of pharmacoepidemiological study carried out for the first time made it possible to investigate the 
dynamics of specialists’ adherence to guidelines of stable angina pharmacotherapy in routine outpatient clinical practice.
Keywords
antianginal therapy, antiplatelets, ACE inhibitors, beta-adrenoblockers, guideline adherence, guideline implementation, 
modifiable risk factors , pharmacoepidemiology, prescription rates, routine outpatient practice, secondary prevention, 
stable angina, statins.
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Introduction
Cardiovascular disease (CVD) remains the most common 
cause of death in Europe, accounting for 45% of all de-
aths (49% of all deaths in women and 40% of all deaths 
in men). In Europe more than 4 million people die from 
CVD across the continent every year (Townsend et al. 
2016). The contribution of CVD to total mortality in Rus-
sia is 57% (Volkova et al. 2015).
Taking into account the fact that ischemic heart disease 
(IHD) still represents the most common cause of death 
worldwide producing inestimable invaluable social and 
economic costs, improving prevention measures is cru-
cial (Chapman et al. 2016). At present there is compelling 
evidence of the effectiveness of secondary prevention in 
reducing CVD morbidity and mortality (Pogosova 2014).
The most common form of IHD is stable angina. Onset 
of this form occurs much earlier in younger Russian pa-
tients than in patients from other countries (Shalnova and 
Deev 2011). This feature emphasizes the importance of 
preventive pharmacotherapy aimed at prophylaxis of seri-
ous complications. It is also important to study pharmaco-
logical correction of angina pectoris because it reflects the 
quality of therapy of the main symptom of stable angina 
and makes it possible to indirectly form an opinion about 
the general trend of the “real” clinical practice in the treat-
ment of IHD (Solyanik et al. 2011).
Despite the wide implementation and regular updatеs 
of treatment guidelines, the gap in the use of guideline 
recommended medications remains significant as shown 
in many previous studies and registries of different pa-
tient populations with CVD. This problem exists not 
only in Russia, but also in other countries (Oganov et al. 
2007, Tolpygina and Martsevich 2016, Abtan et al. 2016, 
Eastaugh et al. 2005 , Kotseva et al. 2017 , Ferrari et al. 
2015, Olomu et al. 2014, Wilkins et al. 2017).
One of the possible solutions as shown by Western prac-
tice is the regular conduct of pharmacoepidemiological 
studies and registries. Such studies serve as the main source 
of feedback on prescription rate of guideline recommended 
medication. The results of such studies allow not only as-
sess the status of the problem in dynamics, but can also be 
used to develop various administrative measures and edu-
cational programs for healthcare professionals and patients.
Only a limited number of pharmacoepidemiological 
studies focused on the population of stable angina patients 
have been done by now. Most of the studies were aimed 
at patients with history of myocardial infarction (MI) and 
revascularization procedures. A possible reason could be 
that prognosis of a patient with stable IHD is considered 
to be relatively favorable.
Among the major international studies and registries 
with Russian participation, it is necessary to mention 
ATP (Oganov et al. 2003) and CLARIFY (Shalnova et al. 
2013). The results showed that in the Russian population 
dominating were the patients with more severe functional 
classes of stable angina. These studies also revealed prob-
lems with controlling the target level of blood pressure 
(BP), blood lipids and adequate lipid lowering therapy, 
frequent use of clinically insignificant dosages and the 
high prevalence of risk factors (RF), such as smoking, 
overweight and diabetes mellitus (DM). At the same time, 
Russian clinics involved were mainly institutions with a 
high level of medical care so the obtained data could be a 
bit “distorted” in a better way. Thus, the results of nation-
al registry “PROGNOZ IHD” demonstrated low prescrip-
tion rate of drugs recommended by secondary prevention 
guidelines before admission of patients to cardiology set-
tings and a significant increase in their prescription rate 
during in-house period (Tolpygina and Martsevich 2016).
Despite the persisting need in the results of this type 
of pharmacoepidemiological analysis and its relevance to 
Russian healthcare, recently there has been a tendency to 
reduce the number of major studies in this field (Petrov 
2006). Taking into account regular updates of foreign and 
national guidelines of secondary prevention and pharma-
cotherapy of CVD, it seems essential to carry out such 
pharmacoepidemiological studies at intervals of four to 
six years on a regular basis, including separate studies at 
regional level and in individual medical institutions.
Objective
To investigate the dynamics of drug prescription rates 
in patients with stable angina over the five-year period 
on the example of routine clinical practice of outpatient 
cardiology institution of Moscow for the purpose of fu-
rther eliminating the prescribing gap for guideline recom-
mended pharmacological strategies in treating patients 
with IHD (pharmacoepidemiological study).
Materials and methods
Our research was designed as a retrospective pharmaco-
epidemiological study, including two stages with a five-
year interval using cross-section method at every stage. 
The object of the research was source medical documen-
tation – outpatient records. The study was approved by 
the Ethical Committee of Cardiology Dispensary #2 of 
Healthcare Department of Moscow”. The scheme of the 
study is shown in Figure 1.
At the first stage, a retrospective analysis of medical 
records of patients with stable angina who primarily vis-
ited cardiology clinic in Moscow in 2006 was conducted. 
The main variables of interest were the prescription rates 
of medications assigned by cardiologists and the degree 
of specialists’ attention to modifiable risk factors of IHD. 
The obtained results revealed a significant prescribing 
gap for guideline recommended medications and low 
adherence of cardiologists to national IHD management 
guidelines. On basis of the results of the first stage, some 
practical activities (use of reminder templates, series of 
lectures, administrative incentives) were introduced with-
in the institution to increase compliance of specialists 
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with clinical guidelines. The second stage was conducted 
basically in the same methodological way and aimed to 
assess the degree of success of complex practical activi-
ties carried out over the five-year period.
The inclusion of patient medical records into each of 
the samples was carried out by randomization from re-
cords of patients who primarily visited the institution 
during the analyzed period. The comparative analysis in-
cluded the data of 2915 outpatient medical records at the 
first stage and 1633 at the second stage.
Information from patient records was transferred to a 
specially designed case report form (CRF). CRF included 
the following sections: patient’s social status and demo-
graphic data, medical history, instrumental and laboratory 
tests results, non-pharmacological correction of RF and 
drug therapy.
Pharmacotherapy (both preventive and anti-ischemic) 
was analyzed for prescription rates of main groups of drugs 
and single medications, as well as for dosage regimens. Pre-
scribed pharmacotherapy was compared to the recommen-
dations of national guidelines for secondary prevention and 
pharmacotherapy of IHD available at the period of study 
stages (Chazov et al. 2004, Akchurin et al. 2008). The prev-
alence and correction of modifiable RF were identified by 
capture degree of this information in patient medical records.
Data from CRFs was transferred to MS Excel data-
base. All statistical tests were performed using SPSS 
PASW Statistics 22. Continuous variables were expressed 
as mean and standard deviation, median and 25th and 75th 
percentiles, minimum and maximum values. Categorical 
variables were expressed as frequencies and percentag-
es. Student’s t-test was used to compare normally dis-
tributed continuous data from two independent samples. 
Mann-Whitney U test was used in case of different distri-
bution and for ordinal scale parameters. Chi square tests 
were used for nominal variables. In case of restrictions 
for Chi square test, Fisher’s exact test was used. Multi-
ple comparisons of ordinal data were performed using 
Mann-Whitney U test. In case of significant differences, 
pairwise comparisons were performed using the Fisher’s 
exact test. Statistical significance was assessed between 
the data from the first and the second stage of the study. A 
p-value <0.05 was considered significant.
Results and discussion
Comparative analysis of patients’ population
The main demographic and medical history data is pre-
sented in Table 1. Women continue to dominate in the 
gender structure of the analyzed population. However, 
the analysis of the data revealed a decrease in the number 
of female patients and an increase in the number of male 
subjects at the second stage of the study.
Over the period of five years, the mean age of a patient 
with stable angina remained almost the same: 65.73±9.10 
years and 66.78±9.46 years, respectively. The analysis of 
the dynamics of patient age distribution revealed that the 
majority of subjects belonged to the age group over 60 
years. At both stages of the study, there were less than 
30% of patients under 60 years of age. Patients with stable 
angina class II and class III according to the Canadian 
Cardiovascular Society (CCS) classification continued to 
dominate within the study population at each stage. 
High frequency of cardiovascular concomitant diseas-
es was revealed in addition to the history of stable angina, 
according to the patients’ medical records. At the second 
stage of the study, the following conditions were detected 
significantly more often: hypertension, chronic heart fail-
ure (CHF), diabetes mellitus, and various heart rhythm 
disturbances. The number of patients with prior MI in-
creased more than 1.5 times, which can be explained by 
lack of secondary prevention measures.
Figure 1. Scheme of retrospective two-stage pharmacoepidemiological study conducted in a specialized outpatient institution.
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Analysis of the prescription rates dynamics of secon-
dary prevention drugs in patients with stable angina
For patients with stable angina, an integral part of pre-
venting CVDs and their complications, according to the 
Russian and international clinical guidelines, is the pre-
scription of drugs with a proven ability to prevent the 
risk of cardiovascular events – antiplatelet agents, sta-
tins, beta-adrenoblockers (BBs) (history of MI or CHF) 
and angiotensin-converting enzyme (ACE) inhibitors (if 
intolerable or contraindicated – angiotensin II receptor 
blockers (ARBs)). Despite the fact that BBs are impor-
tant for improving the prognosis in patients with stable 
angina, the data obtained on prescription rates and dosa-
ge regimen of BBs is presented within the analysis of an-
ti-ischemic pharmacotherapy. Furthermore, BBs are the 
first line drugs to relieve angina symptoms, according to 
guidelines.
Dynamics of prescription rates of secondary preven-
tion drugs recommended to patients with stable angina is 
presented in Table 2. It should be noted that significant 
changes were revealed in comparison with the first stage 
of the study: a higher frequency of recommendations for 
antiplatelets and an almost threefold increase in the fre-
quency of prescribing statins. The use of ACE inhibitors 
remained at the same level, whereas the frequency of 
ARBs increased significantly.
At the same time, antiplatelet agents and statins (must 
be prescribed to all patients with stable angina) were rec-
ommended only to 665 patients at the second stage of the 
study (40.7%). Significant changes were also detected in 
prescription rates of single medications and their dosage 
regimens in each pharmacological group.
Analysis of the prescription rates dynamics of antipla-
telet agents
A significant increase in antiplatelets use (up to 83.0%) 
was found. However, the same value was 90% or more 
in Russian population of patients, looking at the results 
of studies PROGNOZ IHD (Tolpygina and Martsevich 
2016), EUROASPIRE IV (Pogosova et al. 2016), CLA-
RIFY (Shalnova and Deev 2011).
Prescription rates of acetylsalicylic acid (ASA) as 
monotherapy decreased significantly. This was partial-
ly due to an increase in use of ASA in combination with 
clopidogrel. Dual antiplatelet therapy (DAPT) was im-
plemented into clinical practice at the time of the second 
stage of the study (Table 3). At the same time, the propor-
tion of patients with indications for DAPT (one-year his-
tory of MI and/or interventional procedure) was 14.8%.
Prescription rates of daily ASA doses also changed 
over the five-year period. The number of patients receiv-
ing ASA at adequate doses of 100 mg and 75 mg increased 
significantly (Table 4). ASA 50 mg was also prescribed 
frequently in spite of the fact that the guidelines instruct 
to use ASA at doses of 75-150 mg. As a positive aspect, it 
should be noted that physicians almost stopped to use the 
dose of 125 mg which was prescribed as “aspirin ¼” and 
gave favor to ASA drugs in form of tablets coated with an 
intestinal membrane or ASA with antacids (magnesium 
hydroxide).
In general, the changes which had happened over the 
five-year period in antiplatelet pharmacotherapy can be 
assessed positively. But still significant reserves remain 
for further optimization of DAPT as well as for prescrip-
tions rates and adequate dosage regimens.
Table 1. Demographics and clinical characteristics of the patient populations under study
Variables 2006 (n=2915) 2011 (n=1633)
Gender:
Male, n (%) 977 (33.5) 693 (42.4)*
Female, n (%) 1936 (66.4) 940 (57.6)*
Age (y), mean±SD 65,73±9,10 66,78±9,46*
Angina CCS Class:
I, n (%) 91 (3.1) 40 (2.4)
II, n (%) 2458 (84.3) 1420 (87.0)*
III, n (%) 305 (10.5) 154 (9.4)
IV, n (%) 3 (0.1) 2 (0.1)
Prior myocardial infarction, n (%) 640 (22,0) 624 (38.2)*
Arterial hypertension, n (%): 2674 (91.7) 1526 (93.4)*
Grade 1 108 (4.0) 52 (3.4)
Grade 2 689 (25.8) 345 (22.6) *
Grade 3 1826 (68.3) 1104(72.3)*
Chronic heart failure, n (%) 1562 (53.6) 1254 (76.8)*
Prior stroke, n (%) 152 (5.2) 119 (7.3)*
Diabetes mellitus, n (%) 398 (13.7) 357 (21.9)*
Different types of arrhythmias, n (%) 650 (22.3) 439 (26.9)*
Note: *p˂0.05 in comparison with the year of 2006; CCS – Canadian Cardiovascular Society.
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Table 3. Dynamics of prescription rates of antiplatelet agents
Antiplatelets
First stage Second stage
Statistical significance
Number of patients % Number of patients %
ASA (including combination medications) 1627 99.3 1256 93.0 p<0.05
Dual antiplatelet therapy (ASA + 
Clopidogrel) 3 0.2 73 5.4 p<0.05
Clopidogrel 5 0.3 21 1.6 p<0.05
Ticlopidine 4 0.2 1 0.1 p>0.05
Total: 1639 100 1351 100
Note: ASA – acetylsalicylic acid.
Table 4. Dynamics of prescription rates of daily ASA doses
Daily ASA doses (mg)
First stage Second stage
Statistical significance
Number of patients % Number of patients %
500 1 0.1 – – –
250 7 0.4 – – –
150 14 0.9 13 1.0 p>0.05
125 614 37.7 6 0.5 p<0.05
100 782 48.0 945 71.1 p<0.05
75 28 1.7 150 11.3 p<0.05
50 117 7.2 194 14.6 p<0.05
No data 67 4.1 21 1.6 p<0.05
Total 1630 100 1329 100
Note: ASA – acetylsalicylic acid.
Table 2. Dynamics of prescription rates of secondary prevention drugs
Pharmacological groups
First stage (n=2915) Second stage (n=1633)
Statistical significance
Number of patients % Number of patients %
Antiplatelet agents 1639 56.2 1351 82.7 p<0.05
Statins 469 16.1 745 45.6 p<0.05
ACE inhibitors (including 
combination medications) 2028 69.6 1104 67.6 p>0.05
ARBs (including combination 
medications) 282 9.7 240 14.7 p˂0.05
Note: ACE – angiotensin-converting enzyme; ARB – angiotensin II receptor blockers.
Analysis of the prescription rates dynamics of statins
The number of important changes were revealed in sta-
tin therapy along with a significant increase in statin use 
frequency on the whole. Cardiologists significantly more 
often recommended atorvastatin at the second stage of the 
study, but simvastatin prescription rate comparably re-
duced. Rosuvastatin prescriptions were very rare at both 
stages, possibly due to its high cost and availability of 
only one analogue drug. Such medications as fluvastatin 
and lovastatin were not used at the second stage (Table 5).
The analysis of dosage regimens of statins demon-
strated an increased use of leading statins in higher dos-
es. Thus, simvastatin 20 mg was prescribed significantly 
more often and simvastatin 10 mg – almost twice as rarely 
at the second stage of the study. The dose of 40 mg was 
prescribed only in a few cases at both stages (Table 6).
More than 50% of patients received atorvastatin 10 mg 
at both stages of the study despite the significant increase 
in its use of 20 mg dose. Atorvastatin 40 mg was pre-
scribed only in a few cases at the second stage (Table 7).
On one hand, the above results look promising and 
can contribute to improving the efficacy of lipid-lowering 
pharmacotherapy and to achieving target levels for total 
cholesterol (TC) and low-density lipoprotein cholesterol 
(LDL-C). But on the other hand, more than 50% of pa-
tients have not received statins as part of secondary pre-
vention therapy.
Analysis of the prescription rates dynamics of ACE in-
hibitors and angiotensin II receptor antagonists
Both monotherapy and combination drugs (fixed combi-
nations with diuretics or calcium antagonists) were taken 
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into account when analyzing the use of ACE inhibitors 
and ARBs.
The prescription rate of ACE inhibitors as a whole 
group remained at the level of 70% throughout the five-
year period. The most frequently prescribed drugs re-
mained enalapril, perindopril and fosinopril. At the same 
time, the enalapril prescription rate increased significant-
ly at the second stage of the study. Perhaps this happened 
due to its proven efficacy in patients with CHF and MI, 
whose number was higher at the second stage of the study. 
The prescription rates of perindopril and lisinopril also 
increased; however, the rate of fosinopril prescription 
decreased. The proportion of other ACE inhibitors (cap-
topril, ramipril, quinapril) decreased significantly. Espe-
cially strange was the reduction in the use of ramipril be-
cause, according to the guidelines, ramipril is a preferred 
ACE inhibitor for patients with stable angina (Table 8).
The dosage regimen analysis revealed significant 
changes only for enalapril. A significant decrease in use 
of enalapril at higher daily doses of 20 mg and 40 mg was 
accompanied by an increased use of minimal and average 
doses – 2.5 mg, 5 mg and 10 mg (Table 9).
It was necessary to take into account that at the time 
of the first stage of the study, perindopril was marketed 
as perindopril tretbutylamine form and at the time of the 
second stage – as perindopril arginine form. The doses 
of tertbutylamine perindopril – 2 mg, 4 mg and 8 mg – 
correspond to the doses of 2.5 mg, 5 mg and 10 mg of 
perindopril arginine. Dosage regimen of perindopril was 
similar at both stages of the study. Perindopril at the dose 
of 5 mg was recommended to 184 patients (47.8%) at the 
first stage and to 134 patients (50.4%) at the second stage. 
Perindopril at the dose of 2.5 mg was recommended to 
140 patients (36.2%) at the first stage and to 79 patients 
(29.7%) at the second stage. Perindopril was prescribed 
to 50 patients (12.9%) at the first stage and 43 patients 
(16.2%) at the second stage (p>0.05) at the maximal daily 
dose of 10 mg.
Due to the fact that according to the guidelines ACE 
inhibitors should be replaced by ARBs in cases of intoler-
ance or contraindication, it seemed important to analyze 
prescription rates of ARBs (Table 10). Losartan remained 
the most commonly used drug among ARBs (p.>0.05). 
The frequency of valsartan prescriptions was about 10% 
at each stage of the study. Telmisartan, candesartan, epro-
sartan, olmesartan were recommended in a few cases.
Despite a significant increase in prescription rates of 
losartan at the dose of 100 mg, the dose of 50 mg was still 
prescribed in more than 50% cases at both stages of the 
study. The dose of 12.5 mg was not recommended at the 
second stage, while the prescription frequency of the dose 
of 25 mg increased significantly (Table 11).
Table 5. Dynamics of prescription rates of statins
Statins
First stage Second stage
Statistical significance
Number of patients % Number of patients %
Atorvastatin 216 46.1 394 52.9 p<0.05
Simvastatin 248 52.9 339 45.5 p˂0.05
Rosuvastatin 1 0.2 12 1.6 p<0.05
Lovastatin 3 0.6 – – –
Fluvastatin 1 0.2 – – –
Total: 469 100 745 100
Table 6. Dynamics of prescription rates of daily Simvastatin doses
Daily Simvastatin doses (mg)
First stage Second stage
Statistical significance
Number of patients % Number of patients %
5 1 0.4 2 0.6 p>0.05
10 149 60.1 122 36.0 p<0.05
20 85 34.3 205 60.5 p<0.05
40 8 3.2 8 2.4 p>0.05
No data 5 2.0 2 0.6 p>0.05
Total 248 100 339 100
Table 7. Dynamics of prescription rates of daily Atorvastatin doses
Daily Atorvastatin doses (mg)
First stage Second stage
Statistical significance
Number of patients % Number of patients %
5 1 0.5 – – –
10 150 69.4 212 53.8 p<0.05
20 64 29.6 165 41.9 p<0.05
40 – – 14 3.6 –
No data 1 0.5 3 0.8 p>0.05
Total 216 100 394 100
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Table 10. Dynamics of prescription rates of angiotensin II receptor antagonists
Angiotensin II receptor 
antagonists
First stage Second stage
Statistical significance
Number of patients % Number of patients %
Losartan 249 88.3 209 87.1 p>0.05
Valsartan 24 8.5 26 10.8 p>0.05
Telmisartan 4 1.4 1 0.4 p>0.05
Eprosartan – – 1 0.4 –
Candesartan – – 2 0.8 –
Olmesartan – – 1 0.4 –
Irbesartan 5 1.8 – – –
Total: 282 100 240 100
Table 11. Dynamics of prescription rates of daily Losartan doses
Daily Losartan
doses (mg)
First stage Second stage
Statistical significance
Number of patients % Number of patients %
12.5 16 6.4 – – –
25 6 2.4 17 8.1 p<0.05
50 192 77.1 140 67.0 p<0.05
100 26 10.4 40 19.1 p<0.05
No data 9 3.6 12 5.7 p>0.05
Total 249 100 209 100
Table 8. Dynamics of prescription rates of ACE inhibitors
ACE inhibitors
First stage Second stage
Statistical significance
Number of patients % Number of patients %
Enalapril 883 43.5 558 50.5 p<0.05
Perindopril 386 19.0 266 24.1 p<0.05
Fosinopril 413 20.4 156 14.1 p<0.05
Lisinopril 91 4.5 95 8.6 p<0.05
Ramipril 48 2.4 11 1.0 p<0.05
Captopril 94 4.6 9 0.8 p<0.05
Quinapril 108 5.3 7 0.6 p<0.05
Trandolapril – – 1 0.1 –
Zofenopril – – 1 0.1 –
Moexipril 1 0.1 – – –
Cilazapril 1 0.1 – – –
Spirapril 3 0.2 – – –
Total: 2028 100 1104 100
Note: ACE – angiotensin–converting enzyme.
Table 9. Dynamics of prescription rates of daily Enalapril doses 
Daily Enalapril doses (mg)
First stage Second stage
Statistical significance
Number of patients % Number of patients %
40 62 7.0 23 4.1 p<0.05
30 13 1.5 1 0.2 p<0.05
20 386 43.7 163 29.2 p<0.05
15 2 0.2 2 0.4 p>0.05
10 288 32.6 212 38.0 p<0.05
5 79 8.9 100 17.9 p<0.05
2,5 27 3.1 49 8.8 p<0.05
1,25 – – 2 0.4 –
No data 26 2.9 6 1.1 p>0.05
Total 883 100 558 100
Summing up the results describing the dynamics of 
prescriptions rates of ACE inhibitors and ARBs, it should 
be noted that the proportion of patients with stable angi-
na receiving these medications increased over five years. 
The tendency regarding the use of minimal and average 
doses remains.
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Analysis of the prescription rates dynamics of an-
ti-ischemic drugs in patients with stable angina
The main purpose of stable angina treatment is not only 
to improve prognosis (prevention of complications and 
mortality), but also to improve the quality of patients’ life 
(associated with a lower frequency and intensity of angina 
attacks).
The Russian and international guidelines recommend 
the following pharmacological groups of anti-ischemic 
drugs: beta-blockers, calcium channel blockers (CCBs), 
long-acting nitrates, If-channel blockers (selective inhibi-
tion of the sinus node I(f) pacemaking current), K+-chan-
nel activators (stimulation of ATP-sensitive potassium 
channels), myocardial cytoprotectors – trimetazidine and 
ranolazine. The analysis of the prescription rates dynam-
ics of the main groups of anti-ischemic drugs revealed 
significant changes (Table 12).
Above all, a higher prescription rate of BBs and a 
lower prescription rate of long-acting nitrates should be 
noted. Also, the second stage results revealed significant 
reduction in prescription rates of CCBs and trimetazidine.
Analysis of the prescription rates dynamics of be-
ta-adrenoblockers
The prescription rate of the group of BBs increased by 
10.7% over the five-year period. That could be recognized 
as a positive trend. The analysis of prescription rates of 
different BBs identified a number of significant changes. 
Thus, bisoprolol was prescribed almost twice as often and 
took a leading position, replacing metoprolol at the second 
stage of the study. Specialists started prescribing nebivolol 
more frequently and atenolol – less. Other BBs had a very 
small share of prescriptions within the group (Table 13). 
A significant increase in the use of bisoprolol and nebi-
valol can be explained by a larger proportion of patients 
with DM and chronic obstructive pulmonary disease at the 
second stage of the study. It is common knowledge that 
these drugs are more cardioselective in comparison with 
other BBs. Absence of prescriptions of non-selective pro-
pranolol at the second stage is definitely a positive finding.
The analysis of dosage regimens of BBs revealed sig-
nificant changes only regarding bisoprolol. Over the five-
year period, the prescription rate of the dose of 5 mg de-
creased, while the rate of the dose 10 mg increased (Table 
14). Bisoprolol at the dose of 20 mg was recommended 
only at the second stage of the study in individual cas-
es. The minimal therapeutic dose of 2.5 mg started being 
used more often.
Along with bisoprolol, other BBs were still prescribed 
at minimal doses: metoprolol 50 mg – 56.3% (451 pa-
tients) and 51.5% (171 patients), atenolol 50 mg – 63.7% 
(116 patients) and 62.2% (23 patients) at the first and the 
second stage of the study, respectively. The results ob-
tained on BB dosage regimens can be explained by high 
comorbidity rates (CHF, DM, COPD) requiring the use of 
minimal doses with gradual titration.
The study results demonstrated positive dynamics in 
terms of prescription rates of BBs and a more frequent 
choice of cardioselective medications. However, the fact 
that at the second stage BBs were not prescribed to ap-
proximately 25% of patients causes concern.
Analysis of prescription rates dynamics of calcium 
channel blockers
Calcium channel blockers are second-line agents (in ac-
cordance with the guidelines of the Russian Society of 
Cardiology effective at time of the second stage of the 
study) in patients with stable angina and recommended 
in cases of poor tolerance or low efficacy of BBs (Class 
I, Level A). The study results demonstrated the reduction 
in prescription rates of CCBs over the five-year period 
(p<0.05). Within the group, dihydropyridines CCBs were 
prescribed in major cases (over 80%). Non-dihydropyri-
dine CCBs were prescribed in 18.7% of cases at the first 
stage and in 15.8% of cases at the second stage. High pre-
scription rates of dihydropyridines CCBs were most like-
ly caused by high prevalence of hypertensives (more than 
90%) at both study stages. It is important to mention that 
amlodipine prescription rate increased and the nifedipine 
rate decreased (Table 15). The fact that specialists prefer-
red amlodipine to nifedipine is undoubtedly recognized as 
a positive trend.
It is also very important to note the revealed chang-
es in amlodipine dosage regimen. The dose of 5 mg was 
prescribed at a lower rate, but the maximal recommended 
therapeutic dose of 10 mg was prescribed more often at 
the second stage of the study (Table 16). The dose of 2.5 
mg was prescribed in 6.4% and 6.5% of cases at the first 
and the second stage, respectively. The use of this low 
dose might be justified by taking into account a large pro-
portion of elderly patients and high prevalence of CHF.
Analysis of the prescription rates dynamics of long-ac-
ting nitrates
If CCB monotherapy or combination therapy of CCB 
and BB is ineffective, it is necessary to replace CCB by 
long-acting nitrate, according to the current clinical gui-
delines. The results of the present study revealed a signi-
ficant decrease in nitrates use that can be recognized as a 
positive trend. There were no significant changes in the 
group structure. Cardiologists continued to recommend 
isosorbide dinitrate in more than 50% of cases.
Analysis of the prescription rates dynamics of other 
anti-ischemic drugs
Following the actual classification, among the anti-ische-
mic medications recommended for the treatment of stable 
angina are also ivabradine, nicorandil, ranolazine, and tri-
metazidine. The present paper looked only at the prescrip-
tion dynamics of ivabradine and trimetazidine. Nicorandil 
and ranolazine were not included into the guidelines ef-
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Table 15. Dynamics of prescriptions rates of calcium channel blockers
Calcium channel blokers
First stage Second stage
Statistical significance
Number of patients % Number of patients %
Amlodipine 511 44.3 345 59.2 p<0.05
Nifedipine 354 30.7 96 16.5 p<0.05
Felodipine 72 6.2 48 8.2 p>0.05
Lercanidipine 1 0.1 2 0.3 p>0.05
Verapamil 164 14.2 71 12.2 p>0.05
Diltiazem 52 4.5 21 3.6 p>0.05
Total: 1154 100 583 100
Table 16. Dynamics of prescription rates of daily Amlodipine doses
Daily Amlodipin doses (mg)
First stage Second stage
Statistical significance
Number of patients % Number of patients %
2.5 32 6.3 22 6.4 p>0.05
5 325 63.6 185 53.6 p<0.05
10 131 25.6 123 35.7 p<0.05
20 6 1.2 7 2.0 p>0.05
No data 17 3.3 8 2.3 p>0.05
In total 511 100 345 100
Table 12. Dynamics of prescription rates of anti-ischemic drugs
Pharmacological groups
First stage (n=2915) Second stage (n=1633)
Statistical significance
Number of patients % Number of patients %
Beta–blockers 
(including combination medications) 1853 63.6 1213 74.3 p<0.05
Calcium channel blockers 
(including combination medications) 1154 39.6 583 35.7 p<0.05
Long–acting nitrates 906 31.1 429 26.3 p<0.05
Trimetazidine 724 24.8 234 14.3 p<0.05
Ivabradine – – 12 0.7 –
Table 13. Dynamics of prescription rates of beta–blockers
Beta–blockers
First stage Second stage
Statistical significance
Number of patients % Number of patients %
Bisoprolol 610 32.9 667 55.0 p<0.05
Metoprolol 801 43.2 332 27.4 p<0.05
Nebivolol 38 2.1 101 8.3 p<0.05
Carvedilol 110 5.9 74 6.1 p>0.05
Atenolol (including combination 
medications) 182 9.8 37 3.1 p<0.05
Betaxolol 103 5.6 2 0.2 p<0.05
Propranolol 9 0.5 – – –
Total: 1853 100 1213 100
Table 14. Dynamics of prescription rates of daily bisoprolol doses
Bisoprolol daily doses (mg)
First stage Second stage
Statistical significance
Number of patients % Number of patients %
20 – – 3 0.5 –
10 30 4.9 62 9.3 p<0.05
7.5 2 0.3 7 1.0 p>0.05
5 390 63.9 321 48.1 p<0.05
2.5 175 28.7 264 39.6 p<0.05
1.25 2 0.3 7 1.0 p>0.05
No data 11 1.8 3 0.5 p>0.05
Total 610 100 667 100
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fective at time of the study. Ivabradine was included into 
the guidelines only in 2008. The proportion of ivabradine 
prescriptions at the second stage of the study was extre-
mely low. The prescription rate of trimetazidine decre-
ased significantly over the five-year period (Table 12).
Analysis of dynamics of specialists’ attention to modi-
fiable risk factors
An analysis of changes in the degree of cardiologists’ 
attention to modifiable RFs was conducted because all 
the IHD management guidelines recommend to pay spe-
cial attention to the identification and correction of RFs. 
Non-pharmacological measures are considered to be very 
important and include smoking cessation, diet, physical 
activity, weight loss, etc.
A full-scale analysis of the prevalence of modifiable 
cardiovascular RFs in patients with stable angina failed 
due to insufficient capture of relevant information in their 
medical records. Nevertheless, information concerning 
modifiable RFs was captured more frequently at the se-
cond stage of the study. Thus, the data on smoking status 
were present in 27.6% (450 patients) of records, on the 
attitude to alcohol – in 21.5% (351 patients) of records, 
while at the first stage such information was captured only 
in 2.4% (70 patients) and 0.3% (9 patients) of records, 
respectively (p<0.05). Almost no changes were recorded 
regarding the capture of anthropometric parameters al-
lowing to estimate patient’s body mass index (p>0.05). 
This information was present in 13.6% (396 patients) of 
records at the first stage and in 15.7% (256 patients) of 
records at the second stage. None of the medical records 
contained such a parameter as waist circumference. The 
data on physical activity and diet was available in more 
than 95% of records at both stages of the study.
The analysis of data completeness concerning the lip-
id profile revealed a significant increase in the degree of 
cardiologists’ attention to all lipid parameters over the 
five-year period. Almost doubled frequency of capturing 
data on LDL-C levels is undoubtedly a positive trend. 
Attention of specialists to other lipids also became high-
er. Thus, the frequency of capturing data on high density 
lipoprotein cholesterol (HDL-C), triglycerides (TG) and 
total cholesterol significantly increased (Table 17).
The study results demonstrated some positive dynam-
ics regarding completeness of data on modifiable RFs in 
patients’ medical records, but still the degree of special-
ists’ attention to such an important aspect of preventive 
non-pharmacological treatment remains insufficient.
It is also necessary to point out that lack of adequate 
measures for non-pharmacological correction of cardio-
vascular RFs was revealed. Thus, recommendations to do 
physical activity decreased from 23.5% (686 patients) to 
14.9% (244 patients). Only five smokers at the first stage 
and 10 smokers at the second stage received written ad-
vice to stop smoking. The positive dynamics was detected 
in terms of correction of such a risk factor as improper 
nutrition. Frequency of diet recommendations increased 
from 50.1% (1461 patients) to 66.6% (1087 patients).
Conclusion
Thus, the present pharmacoepidemiological study allo-
wed to investigate the dynamics of the gap between the 
guidelines recommended for pharmacological strategies 
and prescriptions when managing patients with stable an-
gina in routine clinical practice of a specialized outpatient 
institution. The results obtained demonstrated an increase 
in prescription rates of key pharmacological groups that 
improve prognosis in IHD: antiplatelets (82.7 vs. 56.2%, 
p<0.05), statins (45.6 vs. 16.1%, p<0.05) and ARBs (14.7 
vs. 9.7%, p<0.05) as well as increasing the frequency of 
recommending BBs (74.3 vs. 63.6%, p<0.05) and long 
acting nitrates (26.3 vs. 31.1%, p<0.05) and CCBs (35.7 
vs. 39,6%, p<0.05) as components of anti-ischemic the-
rapy. The study also revealed an increase in prescripti-
on rates of individual medications at higher daily doses: 
ASA at the dose of 100 mg (71.1 vs. 48.0%, p<0.05), sim-
vastatin and atorvastatin at the dose of 20 mg (60.5 vs. 
34.3%, p<0.05 and 41.9 vs. 29.6%, p<0.05, respectively). 
However, the situation can’t be regarded as satisfactory. 
Therefore, a number of practical recommendations were 
developed to further improve the compliance of specia-
lists’ recommendations with the clinical guidelines at the 
outpatient level of routine medical care. The present stu-
dy significantly contributes to mortality reduction and life 
expectancy increase in patients with IHD by improving 
the adherence of specialists to the clinical guidelines. Yet, 
the problems of patients following a prescribed pharma-
cotherapy and interchangeability of drugs are extremely 
important in this context and, hence, require further study.
In conclusion, the results obtained in the present study 
concerning IHD pharmacotherapy and changes which oc-
curred over the five-year period are consistent in many 
aspects with a number of national and foreign studies on 
the similar problem. This fact emphasizes their credibility 
and importance for practical health care.
Table 17. Dynamics of capturing information on lipid profile in patients’ medical records
Lipids
First stage (n=2915) Second stage (n=1633)
Statistical significance
Number of patients % Number of patients %
Total cholesterol 1291 44.3 1088 66.6 p<0.05
LDL-C 495 17.0 541 33.1 p<0.05
TG 1041 35.7 808 49.5 p<0.05
HDL-C 440 15.1 445 27.3 p<0/05
Note: LDL-C – low-density lipoprotein cholesterol; TG – triglycerides; HDL–C - high density lipoprotein cholesterol.
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